Merck KGaA Reports Results for Evobrutinib in P-III Trial for the Treatment of Relapsing Multiple Sclerosis (RMS)
Shots:
- The P-III (EVOLUTION) clinical trials incl. (evolutionRMS 1) & (evolutionRMS 2) evaluate the safety & efficacy of evobrutinib (45mg, BID, oral) vs teriflunomide (14mg, QD, oral) in patients with RMS incl. relapsing-remitting MS/secondary progressive MS with relapses for up to ~156wks.
- The 1EP of reducing annualized relapse rates (ARR) in patients was not met as the ARR was shown to be 0.11 vs 0.11 & 0.15 vs 0.14 in (evolutionRMS 1) & (evolutionRMS 2) trial, depicting a lower rate than that reported in other P-III studies
- Evobrutinib is a CNS-penetrating, highly selective BTK inhibitor designed to modulate B Cell responses like proliferation, antibody & cytokine release along with modulating macrophage/microglia activation
Ref: Merck | Image: Merck
Related News:- Merck Highlighted 5 Year Results from the P-II OLE Trial of Evobrutinib for Relapsing Multiple Sclerosis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
